Prevalence and management of anemia in renal transplant recipients: a European survey
Yves Vanrenterghem,Claudio Ponticelli,José M. Morales,Daniel Abramowicz,Keshwar Baboolal,Björn Eklund,Volker Kliem,Christophe Legendre,Antonio Luis Morais Sarmento,Flavio Vincenti +9 more
Reads0
Chats0
TLDR
The prevalence of anemia in the transplant recipients was remarkably high and appeared to be associated with impaired renal function and with ACE inhibitors and angiotensin II receptor antagonist use.About:
This article is published in American Journal of Transplantation.The article was published on 2003-07-01 and is currently open access. It has received 303 citations till now. The article focuses on the topics: Anemia & Kidney transplantation.read more
Citations
More filters
Journal ArticleDOI
Immunosuppressive Drugs for Kidney Transplantation
TL;DR: This review considers the use of immunosuppressive drugs in organ transplantation, focusing on renal transplantation.
Journal ArticleDOI
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.
TL;DR: This chapter discusses clinical practice guidelines and recommendations for treatment of anemia in children and adults with Kidney Kidney disease, as well as specific cases of patients with HD-CKD.
Journal ArticleDOI
Renin Angiotensin System Blockade in Kidney Transplantation: A Systematic Review of the Evidence
TL;DR: A systematic review of randomized trials (n = 21 trials with 1549 patients) was conducted to determine the effect of ACE-inhibitor or angiotensin receptor blockers (ARB) use following kidney transplantation as mentioned in this paper.
Journal ArticleDOI
The burden of chronic kidney disease in renal transplant recipients.
TL;DR: CKD and the complications of CKD are highly prevalent in renal transplant recipients and the classification of renal transplant patients by CKD stage may help clinicians identify patients at increased risk and target appropriate therapy to improve outcomes.
Journal ArticleDOI
Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Ashraf Mikhail,Chris Brown,Jennifer Ann Williams,Vinod Mathrani,Rajesh Shrivastava,Jonathan Evans,Hayleigh Isaac,Sunil Bhandari +7 more
TL;DR: The current guidelines provide advice to health care professionals on how to screen chronic kidney disease patients for anaemia, which patients to investigate for other causes of anaemia and when and how to treat patients with different medications, how to ensure safe prescribing of treatment and the drugs used for its treatment.
References
More filters
Journal ArticleDOI
Prediction of Creatinine Clearance from Serum Creatinine
Donald W. Cockcroft,M H Gault +1 more
TL;DR: A formula has been developed to predict Creatinine clearance from serum creatinine (Scr) in adult males: Ccr = (140 – age) (wt kg)/72 × Scr (mg/100ml) (15% less i).
Journal ArticleDOI
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TL;DR: This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
Journal Article
Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection
Josep M. Grinyó,Carl-Gustav Groth,Rudolf Pichlmayr,Sa Sadek,Yves Vanrenterghem,M Behrend,R Luck,Francesc Moreso,J Peeters,J Rodicio,J Morales,Dagfinn Albrechtsen,P Fauchald,Sameh S. Sadek,J. P. A. Lodge,Jp Soulillou,Diego Cantarovich,van Willem Son,Adam Tegzess,Karl-Heinz Wagner,J Erhard,Christina Brattström,Lars Mjörnstedt,M. Wiesel,S. Carl,Hh Neumayer,Hauser,Peter Lang,B Bourgeon,Gunnar Tufveson,G. Gannedahl,Henrik Ekberg,N. Persson,A Tarantino,M Campise,G Thiel,M Zeiler,R Hene,G Ligtenberg,A Morgan,K Rigg,Hooftman L,K Hutchinson +42 more
TL;DR: MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, although the 3 g dose was somewhat less well tolerated.
Journal ArticleDOI
Report of the committee on the genetic constitution of autosomes other than chromosomes 1,2 and 6.
Frank H. Ruddle,P. Meera Khan +1 more
Journal Article
Cardiovascular disease after renal transplantation.
TL;DR: In the absence of controlled intervention trials, the strength of evidence that modifying a risk factor will reduce the incidence of post-transplant cardiovascular disease must rest on: (1) evidence from studies in the general population, (2) observational studies linking the risk factor to CVD in renal transplant recipients, and (3) studies showing that the risk factors can be safely and effectively treated in transplant patients as mentioned in this paper.